Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2019

01-12-2019 | Vulgar Psoriasis | Psoriasis (J Wu, Section Editor)

Review of Outcome Measures in Trials and Practice for Psoriasis

Authors: Payvand Kamrani, Arjun M. Bashyam, Steven R. Feldman

Published in: Current Dermatology Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

The purpose of this review was to determine the most frequently utilized outcome measures in clinical trials and to review the scoring criteria, advantages, disadvantages, and application in research and clinical settings, as well as provide an overview of the published guidelines on the use of outcome measures in clinical practice.

Recent Findings

The most frequently utilized physician-reported outcome measurement instruments in clinical trials from 2018 to 2019 were Physician Global Assessment (PGA), Psoriasis Area Severity Index (PASI), and body surface area. The most frequently utilized patient-reported outcome measurement instruments were Dermatology Quality of Life Index, EQ-5D-5L, and patient global assessment.

Summary

In research, further standardization of outcome measures may allow for more useful comparison of different treatment modalities. In clinical practice, although, the PASI provides a detailed measurement of disease severity, and the PGA score has the advantage of being more clinically useful to physicians and patients.
Literature
1.
2.
3.
4.
5.
Poór AK, Rencz F, Brodszky V, Gulácsi L, Beretzky Z, Hidvégi B, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res. 2017;26(12):3409–19.PubMedCrossRef
6.
Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol. 2006;155(4):707–13.PubMedCrossRef
7.
Loo W, Diba V, Chawla M, Finlay A. Dermatology life quality index: influence of an illustrated version. Br J Dermatol. 2003;148(2):279–84.PubMedCrossRef
8.
Basra M, Fenech R, Gatt R, Salek M, Finlay A. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.PubMed
9.
Langenbruch A, Radtke M, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33(1):123–7.PubMedCrossRef
10.
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194–9.PubMedCrossRef
11.
Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23–31.CrossRef
12.
Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–9.PubMedCrossRef
13.
Feldman S. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat. 2004;15(1):27–9.CrossRef
14.
Po LW. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185–91.CrossRef
15.
Long C, Finlay A, Averill R. The rule of hand: 4 hand areas= 2 FTU= 1 g. Arch Dermatol. 1992;128(8):1129–30.PubMedCrossRef
16.
Stern RS, Armstrong RB, Anderson TF, Bickers DR, Lowe NJ, Harber L, et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol. 1986;15(3):546–52.PubMedCrossRef
17.
• Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8 This is a consensus paper that provides guidelines on what outcome measurements to use endrosed by the National Psoriasis Foundation. This is important as it is a well-known professional soceity offereing guidance on this topic. PubMedCrossRef
18.
Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: a work in progress. Cutis. 2018;101(3S):10–2.PubMed
19.
• Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJ, Bertheussen H, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheum. 2018;70(3):345–55 This paper provided consenses from GRAPPA’s meeting to disucss recommendations for use of measurements and treatment targets. This is important as it provides additional guidelines for which outcome measurements to use. CrossRef
20.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths C, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.PubMedCrossRef
21.
Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10–6.PubMedCrossRef
22.
Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001;45(1):72–6.PubMedCrossRef
23.
• Wechter T, Heath M, Aung-Din D, Sahni D, Cline A, Feldman SR. Current psoriasis efficacy outcome measures in clinical trials. Curr Dermatol Rep. 2018;7(4):261–8 This paper is a review paper in which studied the outcome measurements from 2017–2018. The methods was very similar to the methods used for this paper; however, we incorportated clinical practice guidelines and reviewed measurements for 2018–2019. CrossRef
24.
Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375–81.PubMedCrossRef
Metadata
Title
Review of Outcome Measures in Trials and Practice for Psoriasis
Authors
Payvand Kamrani
Arjun M. Bashyam
Steven R. Feldman
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 4/2019
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-019-00283-0

Other articles of this Issue 4/2019

Current Dermatology Reports 4/2019 Go to the issue

Hospital-Based Dermatology (L Guggina and A Zhou, Section Editors)

Inpatient Management of Mucocutaneous GVHD

Psoriasis (J Wu, Section Editor)

Update on Tildrakizumab for Psoriasis

Wound Care (H Lev-Tov, Section Editor)

Wound Care in the Developing World - Gaps, Opportunities, and Realities

Hospital-Based Dermatology (L Guggina and A Zhou)

Paraneoplastic Syndromes for the Inpatient Dermatologist

Hospital-Based Dermatology (L Guggina and A Zhou)

Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update

Veterinary Dermatology (A Rostaher and N Fischer, Section Editors)

New Strategies for Prevention and Treatment of Insect Bite Hypersensitivity in Horses